Puma Biotechnology Lifts 2026 Outlook, Q1 EPS Beats Estimates Despite Revenue Dip
summarizeSummary
Puma Biotechnology reported a mixed first quarter, with revenue falling to $42 million due to weaker NERLYNX sales. However, the company significantly beat adjusted EPS estimates, reporting -$0.04 against a consensus of -$0.13, and improved net income year-over-year. Crucially, Puma Biotechnology raised its full-year 2026 net product revenue guidance to $202–206 million from $194–198 million, and lifted its net income forecast to $16–19 million from $10–13 million. This positive revision to the full-year outlook, despite the Q1 revenue dip, signals stronger expected performance and resilience against generic competition for NERLYNX, which was highlighted as a challenge in the recent 10-K. Traders will focus on the company's ability to meet this raised guidance and the progress of its ALISCA-Breast1 and ALISCA-Lung1 trials in the second half of 2026.
At the time of this announcement, PBYI was trading at $7.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $369.5M. The 52-week trading range was $2.85 to $7.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.